Market research
I3F.F Infinity Pharmaceuticals, Inc
F EUR Not available
Latest close
Loading market data…
Test a moving-average rule with historical data.
Market facts
- Market cap
- 2M
- P/E ratio
- Not available
- Analyst target
- 9.29
- Dividend yield
- 0.0%
- Beta
- 1.57
Profile
Company facts
- Exchange
- F
- Currency
- EUR
- Sector
- Not available
- Industry
- Not available
- ISIN
- US45665G3039
- Market cap
- 2M
- P/E ratio
- Not available
- Analyst target
- 9.29
- Dividend yield
- 0.0%
- Beta
- 1.57
About
About Infinity Pharmaceuticals, Inc
Infinity Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing novel medicines for people with cancer. The company's product candidate, including eganelisib (IPI-549), an orally administered clinical-stage immuno-oncology product candidate that inhibits the enzyme phosphoinositide-3-kinase-gamma, which is in Phase 2 clinical trials for the treatment of metastatic triple negative breast cancer and urothelial cancer; and Phase 1/1b clinical trials for the treatment of solid tumors. Infinity Pharmaceuticals, Inc. has strategic alliances with Intellikine, Inc. to discover, develop, and commercialize pharmaceutical products targeting the delta and/or gamma isoforms of PI3K; Verastem, Inc. to research, develop, commercialize, and manufacture duvelisib and products containing duvelisib; and PellePharm, Inc. to develop and commercialize rights to its hedgehog inhibitor program, IPI-926, a clinical-stage product candidate, as well as collaboration agreements with F. Hoffmann-La Roche Ltd., and Bristol Myers Squibb Company. Infinity Pharmaceuticals, Inc. was founded in 1995 and is headquartered in Cambridge, Massachusetts. On September 29, 2023, Infinity Pharmaceuticals, Inc. along with its affiliate, a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the I3F.F discussion.
5 years, 5 months ago
Infinity Pharmaceuticals, Inc is currently in a long term uptrend where the price is trading 1.5% above its 200 day moving average.
From a valuation standpoint, the stock is 91.2% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 115.1.
Infinity Pharmaceuticals, Inc's total revenue rose by 41.6% to $436K since the same quarter in the previous year.
Its net income has increased by 6.9% to $-11M since the same quarter in the previous year.
Finally, its free cash flow grew by 11.7% to $-9M since the same quarter in the previous year.
Based on the above factors, Infinity Pharmaceuticals, Inc gets an overall score of 5/5.